Basal Cell Carcinoma During Pregnancy: Case Report
Main Article Content
Abstract
Introduction. Basal cell carcinoma during pregnancy is an entity with an incidence of one case per one thousand pregnant women. It requires timely management, as it may present aggressive behavior and has both psychological and clinical implications for the treatment of the mother and the fetus.
Case Report. A 31-year-old woman at 37 weeks of gestation presented for prenatal care, with a history of gravida 3, para 1, abortion 1, and no family history of cancer. During her initial evaluation, an abdominal dermatologic lesion was noted. At 40 weeks of gestation, she was admitted for labor induction due to gestational age and an amniotic fluid index of 6 cm, which was within normal limits but near the lower threshold. A single live female newborn was delivered with APGAR scores of 8/9. The patient was discharged 24 hours later and referred to dermatology where a biopsy was performed due to suspicion of basal cell carcinoma. Surgical excision with wide margins was subsequently carried out without complications, and the final histopathological report confirmed pigmented nodular basal cell carcinoma with negative margins. The patient experienced a favorable postoperative course.
Conclusion. We present the clinical case of a pregnant patient with an abdominal dermatologic lesion who underwent surgical excision with good clinical progress; the lesion was reported as pigmented nodular basal cell carcinoma.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. McCalmont TH. The shape of basal cell carcinoma. J Cutan Pathol. 2014;41(3):283–285.
II. Pal P, Mallick S, Mandal SK, et al. A human placental extract: in vivo and in vitro assessments of its melanocyte growth and pigment-inducing activities. Int J Dermatol. 2002;41:760–767.
III. López G, editor. Cáncer y embarazo. Pamplona: Editorial Eunsa; 2007.
IV. Güémez-Graniel MF, Plascencia-Gómez A, Graniel-Lavadores MJ, Dzul-Rosado K. Epidemiología del cáncer de piel en el centro dermatológico de Yucatán durante el 2012. Dermatol Rev (Méx). 2015;59:9–18.
V. Christenson LJ, Borrowman TA, Vachon CM, et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA. 2005;294:681–690.
VI. McDaniel B, Steele RB. Basal cell carcinoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [updated 2024 Mar 13].
VII. Weber P, Tschandl P, Sinz C, Kittler H. Dermatoscopy of neoplastic skin lesions: recent advances, updates, and revisions. Curr Treat Options Oncol. 2018;19(11):56.
VIII. Sobanko JF, Lynm C, Rosenbach M. Basal cell carcinoma. JAMA Dermatol. 2013;149(6):766.
IX. Golda N, Hruza G. Mohs micrographic surgery. Dermatol Clin. 2023;41(1):39–47.
X. Sanmartín O, Llombart B, Carretero Hernández G, et al. Sonidegib en el tratamiento del carcinoma basocelular localmente avanzado. Actas Dermo-Sifiliográficas. 2021:295–301.
XI. Campastri A, Bordón MP, Cilio AM, et al. Experiencia del uso de vismodegib para el tratamiento del carcinoma basocelular. Dermatología Argentina. 2022;28(3):119–124.
XII. Cahoon EK, Kitahara CM, Ntowe E, et al. Female estrogen-related factors and incidence of basal cell carcinoma in a nationwide US cohort. J Clin Oncol. 2015;33:4058–4065.
XIII. Fisher GH, Bangash SJ, Mones J, Geronemus RG. Rapid growth of basal cell carcinoma in a multigravid pregnancy. Dermatol Surg. 2006;32(11):1418–1420.